Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial.
Document Type
Article
Publication Date
2-5-2021
Publication Title
Journal of General Internal Medicine
Volume
Online ahead of print
Recommended Citation
Halalau A, Fuller W, Wheeler S. Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial. J Gen Intern Med. 2021 Feb 5. doi: 10.1007/s11606-020-06216-z. Epub ahead of print. PMID: 33547569.
DOI
10.1007/s11606-020-06216-z
ISSN
1525-1497
PubMed ID
33547569
COinS